XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Other (Income) Expense, Net | 9 Months Ended
--- | ---
Sep. 30, 2018
Other Income and Expenses [Abstract] |
Other (Income) Expense, Net | Other (Income) Expense, Net Other (income) expense, net, consisted of:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Interest income | $ | (92 | ) |  | $ | (90 | ) |  | $ | (257 | ) |  | $ | (284 | )
Interest expense | 190 |  |  | 189 |  |  | 569 |  |  | 564 |
Exchange losses (gains) | 42 |  |  | (6 | ) |  | 119 |  |  | 5 |
Equity income from affiliates | (81 | ) |  | (18 | ) |  | (93 | ) |  | (11 | )
Net periodic defined benefit plan (credit) cost other than service cost | (119 | ) |  | (121 | ) |  | (384 | ) |  | (381 | )
Other, net | (112 | ) |  | (161 | ) |  | (466 | ) |  | (244 | )
| $ | (172 | ) |  | $ | (207 | ) |  | $ | (512 | ) |  | $ | (351 | )
The increases in equity income from affiliates in the third quarter and first nine months of 2018 compared with the same periods of 2017 were driven primarily by higher equity income from certain research investment funds. Other, net (as reflected in the table above) includes net gains on securities of $80 million and $202 million in the third quarter and first nine months of 2018, respectively, compared with $25 million and $74 million for the third quarter and first nine months of 2017, respectively. The increase in net gains on securities is attributable to the recognition of unrealized gains on equity securities pursuant to the prospective adoption of ASU 2016-01 on January 1, 2018 (see Note 1). Other, net in the first nine months of 2018 also includes a $115 million gain on the settlement of certain patent litigation (see Note 9). These gains were partially offset by lower income related to AstraZeneca’s option exercise in 2014. Interest paid for the nine months ended September 30, 2018 and 2017 was $535 million and $505 million, respectively.

X
- References No definition available. + Details
Name: | us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -URI http://asc.fasb.org/topic&trid=2122503 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 610 -URI http://asc.fasb.org/topic&trid=49130413 + Details
Name: | us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration